Skip to main content
. Author manuscript; available in PMC: 2015 Mar 3.
Published in final edited form as: J Alzheimers Dis. 2014;41(2):535–549. doi: 10.3233/JAD-132789

Figure 1. Immunization with HJ3.4 and LXR agonist rescue memory deficits in APP23 mice.

Figure 1

11 month old APP23 mice were immunized with HJ3.4 antibody plus/minus LXR agonist T0 for 50 days and cognitive function was assessed with contextual fear conditioning and radial arm water maze (RWM). A, Contextual fear conditioning test demonstrates that treatments were efficient in improving deficits. Analysis is by one-way ANOVA, p < 0.05, Dunnett post-test *, p < 0.05 versus control IgG. Analysis by two-way ANOVA showed that there is an interaction between HJ3.4 antibody and LXR treatment F(1,38)=5.96, p =0.03. B, Cued test shows no statistical difference in performance. Two-way ANOVA analysis shows that there is no interaction between HJ3.4 antibody and LXR treatment F(1,35)=3.37, p =0.06. There was a significant main effect of LXR F(1,35)=5.21, p=0.028 but not of anti-Aβ. C, In RWM test treatment with HJ3.4 antibody and LXR agonist improved spatial memory deficits. Analysis by two-way repeated measures ANOVA shows no interaction between trial block and treatment F(36,477)=0.55, p=0.98. There was a significant main effects of treatment F(4,53)=2,64, p =0.044 and trial block F(9,477)=22.03, p < 0.0001. D, shows the performance on the last trial block of RWM demonstrating that anti- Aβ and LXR restored memory to the level of non-transgenic control. Analysis is by one-way ANOVA, p < 0.01. Dunnett post-test *, p < 0.05 and **, p < 0.01 vs IgG treated mice. N=6–13 male and female mice per group for both experiments.